PDK1 and experimental autoimmune encephalomyelitis: Targeted inhibition of pyruvate dehydrogenase kinase 1 by dichloroacetate inhibited disease progression in mouse models of colitis and experimental autoimmune encephalomyelitis by inhibiting glycolysis, promoting oxidative metabolism and ROS production, and limiting the proliferation and function of Th17 cells [182].